Condition
Chronic Refractory Cough
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Completed2
Terminated1
Unknown1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05570981UnknownPrimary
A Comprehensive Evaluation of the Impact of ATP on Laryngeal Symptoms, Hypersensitivity and Function
NCT02993822Phase 2CompletedPrimary
A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough
NCT03979638Phase 2TerminatedPrimary
A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
NCT01703923Phase 2CompletedPrimary
An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough
Showing all 4 trials